Novo Nordisk A/S (NVO.US) Q1 2026 Earnings Conference Call
Live time: May 6, 2026 11:00 UTC
Novo Nordisk A/S (NVO.US) Q1 2026 Earnings Conference Call
Live time: 05/06/2026 11:00:00 UTC
诺和诺德公司 (NVO.US) 2026 年第一季度业绩电话会
Summary
00:51
Opening Remarks by Michael Novot
Michael Novot, Head of Investor Relations, welcomes participants to Novo Nordisk's Q1 2026 earnings call. He introduces fellow executives, notes a one-hour meeting duration, and reminds attendees about forward-looking statements and their associated risks.
02:54
CEO Mike Gusta EVD U on Strategic Milestones
CEO Mike Gusta EVD U outlines Novo Nordisk's focus areas for 2026, including enhancing competitiveness, advancing R&D pipelines, investing in growth opportunities, and serving over 45 million patients, with more than four million using obesity treatment products—a 50% increase from last year.
03:29
CEO Mike Gusta EVD U on Viggo Pills Launch
CEO Mike highlights the strong launch of Viggo pills in the U.S., serving over one million patients within 16 weeks. Viggo pills represent a new category of oral peptide treatments for obesity and showcase Novo Nordisk's innovative capabilities.
04:30
R&D Update by Mike Gusta EVD U
Mike shares Novo Nordisk's progress in R&D, including six regulatory approvals and over 10 clinical trials initiated in 2026. The company invested approximately 22 billion DKK in R&D and commercial projects.
05:15
Financial Performance by Mike Gusta EVD U
Adjusted sales in Q1 2026 decreased by 4% due to lower realized prices, while operating profit declined by 6% CER. Novo Nordisk returned 38 billion DKK to shareholders through dividends and stock buybacks and raised its guidance for the year.
06:53
Jamie on Wegovy Launch
Jamie highlights the successful launch of Wegovy tablets in the U.S., which offer weight reduction equivalent to injectables and address cardiovascular risks. Over 1.3 million prescriptions were filled in Q1 2026, with 80% of patients being new to GLP-1 therapy.
10:45
Emil on International Sales Growth
Emil reports a 44% increase in international obesity care sales, driven by volume growth but partially offset by lower prices, particularly in China due to NRDL-related price adjustments.
12:05
Carsten Knussen on Financial Strategy
CFO Carsten highlights a 32% reported sales growth to 96.8 billion DKK in Q1 2026, with adjusted sales down 4% due to lower realized prices. The company achieved cost savings of 8 billion DKK, which were reinvested in growth opportunities.
15:52
Chief Scientific Officer Martin Hottlanger on Clinical Highlights
CSO Martin shares key clinical milestones, including U.S. FDA approval for high-dose semaglutide and the initiation of several Phase III trials targeting obesity and related disorders.
24:49
GOVI Dosage Trends — Analyst: Richard Foster (JPMorgan)
Novo Nordisk acknowledges strong market penetration for GOVI oral pills and notes growing weekly trends toward higher doses. Supply chain expansion supports further international launches.
28:26
SG&A and Pricing Strategies — Analyst: Sachin Jain (Bank of America)
Carsten outlines SG&A efficiencies achieved through legal adjustments and disciplined investment in growth drivers. CEO Mike emphasizes dynamic pricing aligned with volume growth trends.
36:12
Next-Gen GLP-1 Differentiation and Leadership View — Analyst: Peter Verdult (BNP Paribas)
Martin emphasizes differentiation in efficacy, tolerability, and dosing frequency for next-gen GLP-1 candidates, while Jamie reflects on consolidating access, sales, and marketing strategies.
52:57
GOVI Tablet Inventory and Co-Formulation — Analyst: Graham Parry (Citi)
Carsten explains a 450 million DKK impact from GOVI tablet inventory builds while Martin reveals co-formulation strategies to accelerate global launches.
Related Notices
Novo Nordisk AS | (6-K) Report by foreign issuer of material events
May 18, 2026 10:29
Novo Nordisk AS | (6-K) Report by foreign issuer of material events
May 13, 2026 07:53
Recent Live Streams
Risk Disclaimer: The content on this page represents the author's personal opinions for general information purposes only and should not be used as a basis for any specific investment, business or commercial decision. It does not represent the position of Longbridge, and the platform makes no guarantees or commitments regarding the authenticity, accuracy or originality of the above content.